scholarly journals Candida albicansEpididymo-Orchitis and Fungemia in a Patient with Chronic Myelogenous Leukemia

1996 ◽  
Vol 7 (5) ◽  
pp. 332-334
Author(s):  
Mark Pimentel ◽  
Lindsay E Nicolle ◽  
Salman Qureshi
Keyword(s):  
Amphotericin B ◽  
Chronic Myelogenous Leukemia ◽  
Low Dose ◽  
Case Reports ◽  
Myelogenous Leukemia ◽  
Current Case ◽  
Characteristic Features ◽  
Immunocompromised State ◽  
Intravenous Amphotericin ◽  
Ultrasonographic Appearance

The fourth reported case of candidal epididymo-orchitis in the literature and the first reported case successfully cured with only low dose amphotericin B is described. A 75-year-old male with chronic myelogenous leukemia presented with acute testicular and epididymal swelling and pain. Subsequent investigations suggested the diagnosis of epididymo-orchitis due toCandida albicans. This was successfully treated with intravenous amphotericin B (total dose of 500 mg). Based on the three previous case reports and the current case several characteristic features that increased the suspicion of this entity were identified. These features include an immunocompromised state, candiduria, specific epididymal ultrasonographic appearance, as well as typical clinical features of epididymo-orchitis.

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside

1993 ◽  
Vol 17 (8) ◽  
pp. 711-715 ◽  
Author(s):  
J. Thaler ◽  
T. Fluckinger ◽  
H. Huber ◽  
A. Lang ◽  
C. Abbrederis ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Interferon Alpha ◽  
Cytosine Arabinoside ◽  
Low Dose ◽  
Myelogenous Leukemia

scholarly journals Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients

2008 ◽  
Vol 88 (4) ◽  
pp. 317-317
Author(s):  
S. Kobayashi ◽  
F. Kimura ◽  
A. Kobayashi ◽  
K. Sato ◽  
K. Motoyoshi
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Low Dose ◽  
Chronic Phase ◽  
Myelogenous Leukemia

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

Blood ◽  
1999 ◽  
Vol 93 (12) ◽  
pp. 4149-4153 ◽  
Author(s):  
Susan O’Brien ◽  
Hagop Kantarjian ◽  
Charles Koller ◽  
Eric Feldman ◽  
Miloslav Beran ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Cytosine Arabinoside ◽  
Low Dose ◽  
Chronic Phase ◽  
Historical Control ◽  
Myelogenous Leukemia ◽  
Simultaneous Administration ◽  
Target Dose ◽  
Median Dose ◽  
Ifn Therapy

Homoharringtonine (HHT) is a novel plant alkaloid that produced a complete hematologic remission (CHR) in 72% of patients with late chronic phase chronic myelogenous leukemia (CML). Cytogenetic (CG) remissions were noted in 31%. In this study, six courses of HHT were administered to 90 patients with early chronic phase CML (< 1 year from diagnosis). Patients then received interferon- (IFN-) with a target dose of 5 MU/m2 daily. Results were compared with those in a prior group of patients treated with IFN-–based therapy between 1982 and 1990. Ninety-two percent of patients achieved CHR with HHT; CG responses were observed in 60% and were major in 27%. Both CHR and CG response rates were significantly higher than those seen in historical control patients after 6 months of IFN- therapy. After receiving HHT, patients required lower doses of IFN- to maintain a CHR. The median dose delivered was 2.4 MU/m2. This reduction in IFN- dose was associated with a lower incidence of myalgia and gastrointestinal (GI) disturbances than that seen in patients treated at the 5 MU/m2 dose. Overall, CG responses were seen in 66% of the patients who received HHT and IFN- compared with 61% of the historical control patients. HHT is a very effective treatment of early chronic phase CML, and ongoing trials are investigating the simultaneous administration of HHT and IFN-, as well as that of HHT and low-dose cytosine arabinoside in patients failing IFN- therapy.

Sign in / Sign up

Export Citation Format

Share Document